Quality assurance and safety of herbal dietary supplements

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 27, Issue 2, 2009, Pages 91-119

  Fu, Peter P ^a   Chiang, Hsiu Mei ^b   Xia, Qingsu ^a   Chen, Tao ^a   Chen, Bai Hsiun ^c   Yin, Jue Jie ^d   Wen, Kuo Ching ^b   Lin, Ge ^e   Yu, Hongtao ^f  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f JACKSON STATE UNIVERSITY   (United States)

Author keywords

Chinese traditional herbs; Herbal dietary supplements; quality assurance; toxicological effects

Indexed keywords

ARISTOLOCHIC ACID; CANCER RISK ASSESSMENTS; CHINESE TRADITIONAL HERBS; DIETARY SUPPLEMENTS; GENOTOXIC; HEALTH PROTECTION; HERBAL DIETARY SUPPLEMENT; HERBAL PLANTS; HERBAL PRODUCTS; SAFETY EVALUATIONS; TOXICOLOGICAL EFFECTS; TUMOR INDUCTION; TUMORIGENICITY;

CONSUMER PROTECTION; NUTRITION; QUALITY ASSURANCE; VITAMINS;

FOOD ADDITIVES;

ARISTOLOCHIC ACID; CARCINOGEN; HERBACEOUS AGENT;

CHEMISTRY; DIET SUPPLEMENTATION; HUMAN; LEGAL ASPECT; MEDICINAL PLANT; PHYTOTHERAPY; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SAFETY; STANDARD;

ARISTOLOCHIC ACIDS; CARCINOGENS; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; HUMANS; PHYTOTHERAPY; PLANTS, MEDICINAL; QUALITY CONTROL; RISK ASSESSMENT;

EID: 66149152684     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590500902885676     Document Type: Article

References (119)

1. Zurer, P, Hanson, D. Chemistry puts herbal supplements to the test. Chemical & Engineering News 2004;82(14):16.
2. Lee, FSC, Wang, X, Fu, PP. Good Agriculture Practice (GAP) for the quality assurance and safety protection of traditional Chinese herbs used in dietary supplements. Am Chem Soc Monograph, in press.
3. FDA Proposal for Dietary Supplements Current. Good Manufacturing Practices (CGMPs). 2003. Available at: http://www.cfsan.fda.gov/~dms/dscgmps3. html
4. World Health Organization. Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants. Nonserial Publication; 2003.
5. Hu, SL. A study of Chinese genuine herbs. Chinese Medicine Publishing Inc; Bejing, China, 1997.
6. Chan, SS, Li, SL, Lin, G. Pitfalls of the selection of chemical markers for the quality control of medicinal herbs. J Food Drug Anal 2007;15:365-371. (Pubitemid 351385209)
7. Chan, PC, Xia, Q, Fu, PP. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. Environ Carcinogen Ecotoxicol Rev 2007;25:211-244. (Pubitemid 47347114)
8. Liu, Y, Liu, SH, Wang, JQ, Sun, SQ. Progress in application of infrared spectroscopy and comparative study of chromatographic fingerprints. Guangpuxue Yu Guangpu Fenxi 2007;27:1093-1097. (Pubitemid 47128428)
9. Chen, J, Lee, FSC, Li, L, Yang, B, Wang, X. Standardized Extracts of Chinese Medicinal Herbs: Case Study of Danshen (Salvia miltiorrhiza Bunge). J. Food Drug Anal 2007;15:347-364. (Pubitemid 351385208)
10. Chan, SS, Cheng, TY, Lin, G. Relaxation effects of ligustilide and senkyunolide A, two main constituents of Ligusticum chuanxiong, in rat isolated aorta. J Ethnopharmacol 2007;111:677-680. (Pubitemid 46617091)
11. Li, SL, Lin, G, Tam, YK. Time-course accumulation of main bioactive components in the rhizome of Ligusticum chuanxiong. Planta Med 2006;72:278-280.
12. Li, SL, Yan, R, Tam, YK, Lin, G. Post-harvest alteration of the main chemical ingredients in Ligusticum chuanxiong Hort Chem Pharm Bul. 2007;55:140-144. (Pubitemid 46067600)
13. Wu, J, Li, L. Determination of the residues of eleven organophosphorus insecticides in Job's-tears by gas chromatography with a nitrogen-phosphorus detector. J AOAC Int 2004;87(5):1260-1263.
14. Leung, KS, Chan, K, Chan, CL, Lu, GH. Systematic evaluation of organochlorine pesticide residues in Chinese materia medica. Phytother Res 2005;19(6):514-8. (Pubitemid 41345529)
15. Hao, LL, Xue, J. Multiresidue analysis of organochlorine pesticides and the application to Chinese herbal medicine. Zhongguo Zhong Yao Za Zhi 2005;30(6):405-9. (Pubitemid 44724687)
16. Tam, JW, Dennehy, CE, Ko, R, Tsourounis, C. Analysis of ephedra-free labeled dietary supplements sold in the San Francisco Bay area in 2003. J Herb Pharmacother 2006;6(2):1-19. (Pubitemid 44964089)
17. Lai, L, Liu, F-S, Hsu, Y-H, Yu, C-L, Hsiao, S-H, Lo, C-F, Lin, J-H. Survey of heavy metals in raw material of traditional Chinese medinice (I), Annual Scientific Report of Bureau of Food and Drug Analysis, Department of Health, Executive Yuan. 2006;24:228-241.
18. Lai, L, Tseng, J-H, Chen, Y-H, Lo, C-F, Lin, J-H. Survey of heavy metals in raw material of traditional Chinese medinice (II), Annual Scientific Report of Bureau of Food and Drug Analysis, Department of Health, Executive Yuan. 2006;24:242-256.
19. Lai, L, Liu, F-S, Hsu, Y-H, Yu, C-L, Hsiao, S-H, Lo, C-F, Lin, J-H. Survey of organochlorine pesticide residues in raw material of traditional Chinese medinice (I), Annual Scientific Report of Bureau of Food and Drug Analysis, Department of Health, Executive Yuan. 2006;24:257-264.
20. Lai, L, Chin, L, Chen, Y-H, Lo, C-F, Lin, J-H. Survey of organochlorine pesticide residues in Chinese herbs and pharmaceutical products (II), Annual Scientific Report of Bureau of Food and Drug Analysis, Department of Health, Executive Yuan. 2006;24:265-273.
21. Wong, TC, Chang, L, Lee, FSC, Wang, X, Fu, PP. A Survey of Heavy Metals and Organochlorine Pesticides Contaminations in Commercial Ling Zhi Products. J Food Drug Anal 2007;15:472-479. (Pubitemid 351385221)
22. Mustafa, O, Brendan,M, Pei, C. Comparison of the terpene lactones and flavonols contents in G. Biloba commercial samples and the NIST standard reference materials using LC/UV/MS. J Food Drug Anal 2007;15:55-62. (Pubitemid 46779706)
23. FDA. Warning on Imported Ginseng. FDA Consumer 2005;39(2).
24. Pailer, MI, Belohlav, I, Simonitsch, E. Konstitution der Aristolochiasauren. Monatsh Chem 1955;86:676-680.
25. Schwetz, BA. From the Food and Drug Administration. JAMA 2001;285:2705.
26. FDA. Dietary Supplements: Aristolochic Acid. 2001. Available at: http://www.cfsan.fda.gov/~dms/ds-bot.html
27. Gold, LS, Slone, TH. Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. N Engl J Med 2003;349:1576-1577. (Pubitemid 37255048)
28. Martena, MJ, van der Wielen, JC, van de Laak, LF, Konings, EJ, de Groot, HN, Rietjens, IM. Enforcement of the ban on aristolochic acids in Chinese traditional herbal preparations on the Dutch market. Anal Bioanal Chem 2007;389:263-275. (Pubitemid 47325230)
29. Cheung, TP, Xue, C, Leung, K, Chan, K, Li, CG. Aristolochic acids detected in some raw Chinese medicinal herbs and manufactured herbal products-a consequence of inappropriate nomenclature and imprecise labelling? Clin Toxicol (Phila) 2006;44:371-378. (Pubitemid 43995176)
30. Yang, HY, Lin, JL, Chen, KH, Yu, CC, Hsu, PY, Lin, CL. Aristolochic acid-related nephropathy associated with the popular Chinese herb Xi Xin. J Nephrol 2006;19:111-114.
31. IARC. Some traditional herbal medicines, some mycotoxins, naphtalene and styrene. In IARC monographs on the evaluation of carcinogenic risks of chemical to humans Lyon, France: IARC; 2002.
32. Nortier, JL, Martinez, MC, Schmeiser, HH, Arlt, VM, Bieler, CA, Petein, M, Depierreux, MF, De Pauw, L, Abramowicz, D, Vereerstraeten, P. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-1692. (Pubitemid 30354515)
33. Vanherweghem, JL, Tielemans, C, Simon, J, Depierreux, M. Chinese herbs nephropathy and renal pelvic carcinoma. Nephrol Dial Transplant 1995;10:270-273.
34. Mengs, U. Acute toxicity of aristolochic acid in rodents. Arch Toxicol 1987;59:328-331.
35. Mengs, U, Stotzem, CD. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch Toxicol 1993;67:307-311. (Pubitemid 23180975)
36. Arlt, VM, Schmeiser, HH, Pfeifer, GP. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 2001;22:133-140. (Pubitemid 32098154)
37. Robisch, G, Schimmer, O, Goggelmann, W. Aristolochic acid is a direct mutagen in Salmonella typhimurium. Mutat Res 1982;105:201-204. (Pubitemid 12029171)
38. Zhang, H, Cifone, MA, Murli, H, Erexson, GL, Mecchi, MS, Lawlor, TE. Application of simplified in vitro screening tests to detect genotoxicity of aristolochic acid. Food Chem Toxicol 2004;42:2021-2028. (Pubitemid 39421503)
39. Mengs, U. On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid. Arch Toxicol 1983;52:209-220. (Pubitemid 13108968)
40. Mengs, U. Tumour induction in mice following exposure to aristolochic acid. Arch Toxicol 1988;61:504-505.
41. Lord, GM, Cook, T, Arlt, VM, Schmeiser, HH, Williams, G, Pusey, CD. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001;358:1515-1516. (Pubitemid 33055708)
42. Vishwanath, BS, Gowda, TV. Interaction of aristolochic acid with Vipera russelli phospholipase A2: its effect on enzymatic and pathological activities. Toxicon 1987;25:929-937.
43. Vanherweghem, JL, Depierreux, M, Tielemans, C, Abramowicz, D, Dratwa, M, Jadoul, M, Richard, C. Vandervelde, D, Verbeelen, D, Vanhaelen-Fastre, R. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-391. (Pubitemid 23048140)
44. Cosyns, JP, Jadoul, M, Squifflet, JP, De Plaen, JF, Ferluga, D, van Ypersele de Strihou, C. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 1994;45:1680-1688. (Pubitemid 24207504)
45. Depierreux, M, Van Damme, B, Vanden Houte, K, Vanherweghem, JL. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 1994;24:172-180. (Pubitemid 24249054)
46. Vanherweghem, LJ. Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med 1998;4:9-13.
47. Vanhaelen, M, Vanhaelen-Fastre, R, But, P, Vanherweghem, JL. Identification of aristolochic acid in Chinese herbs. Lancet 1994;343:174. (Pubitemid 24028653)
48. Nortier, JL, Schmeiser, HH, Muniz Martinez, MC, Arlt, VM, Vervaet, C, Garbar, CH, Daelemans, P, Vanherweghem, JL. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. Nephrol Dial Transplant 2003;18:426-428. (Pubitemid 36181698)
49. Cronin, AJ, Maidment, G, Cook, T, Kite, GC, Simmonds, MS, Pusey, CD., Lord, GM. Aristolochic acid as a causative factor in a case of Chinese herbal nephropathy. Nephrol Dial Transplant 2002;17:524-525. (Pubitemid 34211163)
50. Schmeiser, HH, Bieler, CA, Wiessler, M, van Ypersele de Strihou, C, Cosyns, JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996;56:2025-2028. (Pubitemid 26119902)
51. Lord, GM, Hollstein, M, Arlt, VM, Roufosse, C, Pusey, CD, Cook, T, Schmeiser, HH. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 2004;43:e11-17.
52. Arlt, VM, Alunni-Perret, V, Quatrehomme, G, Ohayon, P, Albano, L, Gaid, H, Michiels, JF, Meyrier, A, Cassuto, E, Wiessler, M. Aristolochic acid (AA)-DNA adductas marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int J Cancer 2004;111:977-980. (Pubitemid 39096251)
53. Cui, M, Liu, ZH, Qiu, Q, Li, H, Li, LS. Tumour induction in rats following exposure to short-term high dose aristolochic acid I. Mutagenesis 2005;20:45-49. (Pubitemid 40333307)
54. Cosyns, JP, Dehoux, JP, Guiot, Y, Goebbels, RM, Robert, A, Bernard, AM, van Ypersele de Strihou, C. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int 2001;59:2164-2173. (Pubitemid 32467608)
55. Gold, L, Zeiger, E, Eds. Handbook of carcinogenic potency and genotoxicity databases. Boca Raton, Fla:CRC Press; 1997. Available at: http://potency.berkeley.edu/:
56. Chen, L, Mei, N, Yao, L, Chen, T. Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol Lett 2006;165:250-256.
57. Chen, T, Guo, L, Zhang, L, Shi, L, Fang, H, Sun, Y, Fuscoe, JC, Mei, N. Gene Expression Profiles Distinguish the Carcinogenic Effects of Aristolochic Acid in Target (Kidney) and Non-target (Liver) Tissues in Rats. BMC Bioinformatics 2006;2 (7 Suppl):S20.
58. Chen, T. Genotoxicity of Aristolochic acid: A Review. J Food Drug Anal 2007;15:387-399. (Pubitemid 351385212)
59. Kessler, DA. Cancer and herbs. N Engl J Med 2000;342:1742-1743. (Pubitemid 30354523)
60. Schwetz, BA. From the Food and Drug Administration. JAMA 2001;285:2705. Available at: http://www.cfsan.fda.gov/~dms/ds-bot.html
61. National Toxicology Program (NTP). Report on Carcinogens Background Document for Aristolochic Acid. Research Triangle Park, NC: NTP; 2008.
62. IARC (International Agency for Research in Cancer). Pyrrolizidine alkaloids. In: IARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals to Man-Some Naturally Occurring Substance Lyon, France: International Agency for Research on Cancer; 1976(vol. 10): 265-342.
63. Mattocks, AR. Chemistry and toxicology of pyrrolizidine alkaloids. London: Academic Press; 1986.
64. Fu, PP, Xia, Q, Lin, G, Chou, MW. Genotoxic pyrrolizidine alkaloids- mechanisms leading to DNA adduct formation and tumorigenicity. Drug Metab Rev 2004;36:1-55.
65. Chan, PC, Haseman, JK, Prejean, JD, Nyska, A. Toxicity and carcinogenicity of riddelliine in rats and mice. Toxicol Lett 2003;144:295-311. (Pubitemid 36966714)
66. Molyneux, JO, Cooke, MP, King, RR, Mohamed, PA. Pyrrolizidine alkaloids in milk; thresholds of toxication. Vet Hum Toxicol 1990;32:94-103.
67. Betz, JM, Eppley, RM, Taylor, WC, Andrzejewski, D. Determination of pyrrolizidine alkaloids in commercial comfrey products (Symphytum sp.). J Pharm Sci 1994;83:649-653. (Pubitemid 24219813)
68. Prakash, AS, Pereira, TN, Reilly, PE, Seawright, AA. Pyrrolizidine alkaloids in human diet. Mutat Res 1999;443:53-67. (Pubitemid 29327266)
69. Chou, MW. Fu, PP. Formation of DHP-derived DNA adducts in vivo from dietary supplements and Chinese herbal plant extracts containing carcinogenic pyrrolizidine alkaloids. Toxicol Ind Health 2006;22:321-327. (Pubitemid 46768766)
70. International Programme on Chemical Safety (IPCS). Pyrrolizidine Alkaloids Health and Safety Guide. Health and Safety Criteria Guide 26. Geneva: WHO; 1989.
71. Yang, YC, Yan, J, Doerge, DR, Chan, P-C, Fu, PP, Chou,MW.Metabolic activation of the tumorigenic pyrrolizidine alkaloids, riddelliine, leading to DNA adduct formation in vivo. Chem Res Toxicol 2001;14:101-109. (Pubitemid 32064380)
72. Chou, MW, Jian, Y, Williams, LD, Xia, Q, Churchwell, M, Doerge, DR, Fu, PP. Identification of DNA adducts derived from riddelliine, a carcinogenic pyrrolizidine alkaloid. Chem Res Toxicol 2003;16:1130-1137. (Pubitemid 37163219)
73. Chou, MW, Yan, J, Nichols, J, Xia, Q, Beland, FA, Chan, PC, Fu, PP. Correlation of DNA adduct formation and riddelliine-induced liver tumorigenesis in F344 rats and B6C3F(1) mice. Cancer Lett 2003;193:119-125. (Pubitemid 36428892)
74. Xia, Q, Chou, MW, Kadlubar, FF, Chan, P-C, Fu, PP. Human liver microsomal metabolism and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine. Chem Res Toxicol 2003;16:66-73. (Pubitemid 36139412)
75. National Toxicology Program (NTP). Report on Carcinogens. Federal Register 2008; 73, No. 84.
76. Fu, PP, Xia, Q, Chou, MW, Lin, G. Detection, hepatotoxicity, and tumorigenicity of pyrrolizidine alkaloids in Chinese herbal plants and herbal dietary supplements. J Food Drug Anal 2007;15: 400-415. (Pubitemid 351385213)
77. Roeder, E. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie 2000;55:711-726.
78. McLean, EK. The toxic actions of pyrrolizidine (senecio) alkaloids. Pharmacol Rev 1970;22:429-483.
79. Lin, G, Cui, YY, Hawes, EM. Characterization of rat liver microsomal metabolites of clivorine, an hepatotoxic otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos 2000;28:1475-1483.
80. Fu, PP, Yang, Y-C, Xia, X, Chou, MW, Cui, YY, Lin, G. Pyrrolizidine alkaloids- tumorigenic components in Chinese herbal medicines and dietary supplements. J Food Drug Analy 2002;10:198-211. (Pubitemid 36204638)
81. Li, S-L, Lin, G, Fu, PP, Chan, C-L, Li, M, Jiang, Z-H, Zhao, Z-H. Identification of five hepatotoxic pyrrolizidine alkaloids in a commonly used traditional Chinese medicinal herb, Herba Senecionis Scandentis (Qianliguang). Rapid Commun Mass Spect 2008;22:591-602. (Pubitemid 351300595)
82. Yan, J, Xia, Q, Fu, PP, Chou, MW. Metabolic activation of retronecine and retronecine N-oxide-formation of DHP-derived DNA adducts. Toxicol Ind Health 2008;24:181-188.
83. Wang, Y-P, Yan, J, Beger, RD, Fu, PP, Chou, MW. Metabolic activation of the tumorigenic pyrrolizidine alkaloid, monocrotaline, leading to DNA adduct formation in vivo. Cancer Lett 2005;226:27-35. (Pubitemid 40943427)
84. Xia, Q, Chou, MW, Lin, G, Fu, PP. Formation of DHP-derived DNA adducts from metabolic activation of clivorine, a presentative otonecine-type pyrrolizidine alkaloid, and Ligularia hodgsonnii hook plant extract. Chem Res Toxicol 2004;17:702-708. (Pubitemid 38669528)
85. Xia, Q, Chou, MW, Edgar, JA, Doerge, DR, Fu, PP. Formation of DHP-derived DNA adducts from metabolic activation of the prototype heliotridine-type pyrrolizidine alkaloid, lasiocarpine. Cancer Lett 2006;231:138-145. (Pubitemid 41779462)
86. Xia, Q, Yan, J, Chou, MW, Fu, PP. Formation of DHP-derived DNA adducts from metabolic activation of heliotrine. Toxicol Lett 2008;178:77-82.
87. Mossoba, MM, Lin, SH, Andrzejewski, D, Sphon, JA. Application of gas chromatography/matrix isolation/fourier transform infrared spectroscopy to theidentification of pyrrolizidine alkaloids from comfrey root (Symphytum officinale L.). J AOAC Int 1994;77(5):1167-1174.
88. Snider, S. Beware the unknown brew. Herbal Teas and Toxicity. FDA Consumer 1991;25(4):30-33.
89. Vollmer, JJ, Steiner, NC, Larsen, GY,Muirhead, KM,Molyneux, RJ. Pyrrolizidine alkaloids: testing for toxic constituents of comfrey. J Chem Educ 1987;64(12):1027-1030.
90. D'Arcy, PF. Adverse reactions and interactions with herbal medicines. Part 1. Adverse reactions. Adverse Drug React Toxicol Rev 1991;10(4):189-208.
91. Bent, S, Goldberg, H, Padula, A, Avins, AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med 2005;20(7):657-61. (Pubitemid 41026255)
92. Rowin, J, Lewis, SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46(6):1775-6.
93. Al-Yahya, AA, Al-Majed, AA, Al-Bekairi, AM, Al-Shabanah, OA, Qureshi, S. Studies on the reproductive, cytological and biochemical toxicity of Ginkgo Biloba in Swiss albino mice. J Ethnopharmacol 2006;107(2):222-8. (Pubitemid 44247440)
94. Yamashita, N, Kawanishi, S. Distinct mechanisms of DNA damage in apoptosis induced by quercetin and luteolin. Free Radic Res 2000;33(5):623-33. (Pubitemid 32103702)
95. Boots, AW, Balk, JM, Bast, A, Haenen, GR. The reversibility of the glutathionylquercetin adduct spreads oxidized quercetin-induced toxicity. Biochem Biophys Res Commun 2005;338(2): 923-929. (Pubitemid 41597730)
96. Boersma, MG, Vervoort, J, Szymusiak, H, Lemanska, K, Tyrakowska, B, Cenas, N, Segura-Aguilar, J, Rietjens, IM. Regioselectivity and reversibility of the glutathione conjugation of quercetin quinone methide. Chem Res Toxicol 2000;13(3):185-91. (Pubitemid 30169963)
97. Choi, EJ, Lee, BH, Lee, K, Chee, KM. Long-term combined administration of quercetin and daidzein inhibits quercetin-induced suppression of glutathione antioxidant defenses. Food Chem Toxicol 2005;43(5):793-8. (Pubitemid 40385120)
98. Walle, T, Vincent, TS, Walle, UK. Evidence of covalent binding of the dietary flavonoid quercetin to DNA and protein in human intestinal and hepatic cells. Biochem Pharmacol 2003;65(10):1603-10. (Pubitemid 36577273)
99. van der Woude, H, Alink, GM, van Rossum, BE, Walle, K, van Steeg, H, Walle, T, Rietjens, IM. Formation of transient covalent protein and DNA adducts by quercetin in cells with and without oxidative enzyme activity. Chem Res Toxicol 2005;18(12):1907-16. (Pubitemid 43023049)
100. Crebelli, R, Aquilina, G, Falcone, E, Carere, A. Urinary and faecal mutagenicity in Sprague-Dawley rats dosed with the food mutagens quercetin and rutin. Food Chem Toxicol 1987;25(1):9-15. (Pubitemid 17030109)
101. NTP. Toxicology and Carcinogenesis Studies of Quercetin (CAS No. 117-39-5) in F344/N Rats (Feed Studies). Research Triangle Park, NC: National Toxicology Program; 1992. Report nr Technical Report Series No. 409.
102. Clouatre, DL. Kava kava: examining new reports of toxicity. Toxicol Lett 2004;150:85-96. (Pubitemid 38447238)
103. Singh, YN. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 2005;100:108-113. (Pubitemid 41073531)
104. Fu, PP, Xia, Q, Guo, L, Yu, H, Chan, P-C. Toxicity of kava kava. J Environ Sci Health, Part, C, Environ Carcinogen Ecotocicol Rev 2008;26:89-112. (Pubitemid 351347047)
105. Humberston, CL, Akhtar, J, Krenzelok, EP. Acute hepatitis induced by kava kava. J Toxicol Clin Toxicol 2003;41:109-113. (Pubitemid 36520458)
106. Stickel, F, Baumuller, HM, Seitz, K, Vasilakis, D, Seitz, G, Seitz, HK, Schuppan, D. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003;39:62-67. (Pubitemid 36724109)
107. Center for Food Safety and Applied Nutrition (CFSAN). U.S. Food and Drug Administration. A Consumer Advisory. Kava-containing dietary supplements may be associated with severe liver injury. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, Maryland, March 25, 2002. Available at: http://www.cfsan.fda.gov/~dms/ds-warn.html
108. Whitton, PA, Lau, A, Salisbury, A, Whitehouse, J, Evans, CS. Kava lactones and the kava-kava controversy. Phytochemistry 2003;64:673-679. (Pubitemid 37176400)
109. Eichelbaum, M, Kroemer, HK, Fromm, MF. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev 1997;27:171-199. (Pubitemid 27417872)
110. Mathews, JD, Riley, MD, Fejo, L, Munoz, E, Milns, NR, Gardner, ID, Powers, JR, Ganygulpa, E, Gununuwawuy, BJ. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988;148:548-555.
111. Zou, L, Harkey, MR, Henderson, GL. Effects of herbal components on cDNAexpressed cytochrome P450 enzyme catalytic activity. Life Sci 2002;71(13):1579-89. (Pubitemid 34808718)
112. Mathews, JM, Etheridge, AS, Black, SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 2002;30:1153-1157. (Pubitemid 35265819)
113. Mathews, JM, Etheridge, AS, Valentine, JL, Black, SR, Coleman, DP, Patel, P, So, J, Burka, LT. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 2005;33:1555-1563. (Pubitemid 41324005)
114. Bressler, R. Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 2005;60:24-25. (Pubitemid 41318296)
115. Hu, Z, Yang, X, Ho, PC, Chan, SY, Heng, PW, Chan, E, Duan, W, Koh, HL, Zhou, S. Herb-drug interactions: a literature review. Drugs 2005;65:1239-1282. (Pubitemid 41038418)
116. Clayton, NP, Yoshizawa, K, Kissling, GE, Burka, LT, Chan, PC, Nyska, A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp Toxicol Pathol 2007;58:223-236. (Pubitemid 44873076)
117. Kaplowitz, N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-310. (Pubitemid 32016915)
118. Johnson, BM, Qiu, SX, Zhang, S, Zhang, F, Burdette, JE, Yu, L, Bolton, JL, van Breemen, RB. Identification of novel electrophilic metabolites of piper methysticum Forst (Kava). Chem Res Toxicol 2003;6:733-740. (Pubitemid 36736604)
119. Federal Register. Final Rule and Interim final rule. June 25, 2007. Available at: http://www.cfsan.fda.gov/~dms/dscgmps7.html